Skip to main content
Medical information Clinical review pending

Genetic Testing

OncoPro PDL1 Circulating Tumor Cells Test

The OncoPro PDL1 Circulating Tumor Cells Test detects circulating tumor cells (CTCs) in the blood, aiding in cancer diagnosis, treatment monitoring, and personalized therapy planning.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
8 mL whole blood collected in a Lavender Top (EDTA) tube.
Results
Results are typically available within 21 working days. Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Ensure the preservative supplied in the kit is added to the EDTA tube using a syringe and needle immediately after collection.
Test priceKSh 105,300

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the OncoPro PDL1 Circulating Tumor Cells Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Monitoring cancer progression or response to treatment.
  • ✓Assessing PDL1 expression on circulating tumor cells.
  • ✓Guiding personalized cancer therapy decisions.
  • ✓Patients with suspected or confirmed cancer.
  • ✓Individuals with risk factors for cancer.
02

In plain language

What this test helps you understand

This test helps oncologists detect circulating tumor cells, assess PDL1 expression on these cells, monitor treatment response, and potentially guide personalized cancer therapy decisions.
The OncoPro PDL1 Circulating Tumor Cells Test is an advanced diagnostic tool used to identify circulating tumor cells (CTCs) within the bloodstream. This test is valuable for cancer management, helping doctors assess the presence of cancer and track how well treatment is working.

This specific test measures the presence of PDL1 expressing CTCs. PDL1 is a protein found on some cancer cells that can influence how the immune system responds to the tumor. Measuring PDL1 expression on CTCs can provide important information about the tumor's characteristics and potential response to certain therapies, assisting in tailoring treatment plans.

This test is often considered for individuals diagnosed with cancer who require ongoing monitoring, those experiencing symptoms potentially related to cancer, or individuals with known risk factors for cancer.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the preservative supplied in the kit is added to the EDTA tube using a syringe and needle immediately after collection.
Sample8 mL whole blood collected in a Lavender Top (EDTA) tube.
MethodologyConfirm with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects CTCs in the blood; it may not detect all types of cancer or all tumors within the body. Results should be interpreted in conjunction with other clinical findings and diagnostic tests. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

CTCs are cancer cells that have broken away from a primary tumor and entered the bloodstream. Detecting them can provide information about the cancer.
PDL1 is a protein that can affect the immune system's response to cancer. Measuring its expression on CTCs can help predict potential response to certain treatments.
No, this test requires a standard blood draw, which is a minimally invasive procedure.
Results should be discussed with your oncologist, who can interpret them in the context of your overall health and medical history.
Yes, a completed OncoPro Liquid Biopsy Clinical Information Form (Form 32) is mandatory for processing the sample.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp